Back to first-pass browser

First-pass extracted concept

acoustic droplet vaporization

Candidate: concept label1 source documents4 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

ADV

Evidence Snippets

Phase-shift droplets undergoing acoustic droplet vaporization (ADV) offer a promising approach for ultrasound-mediated drug delivery.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application potentialsupports2025Source 1DOIPubMed

Phase-shift droplets undergoing acoustic droplet vaporization offer a promising approach for ultrasound-mediated drug delivery with spatiotemporally controlled payload release.

Quoted textsource-backed
Phase-shift droplets undergoing acoustic droplet vaporization (ADV) offer a promising approach for ultrasound-mediated drug delivery, enabling the spatiotemporally controlled release of therapeutic payloads.
Claim 2comparative kineticssupports2025Source 1DOIPubMed

Post-ultrasound payload release rates exceeded bubble growth rates.

Quoted textsource-backed
Notably, payload release rates post-ultrasound exceeded bubble growth rates.
Claim 3mechanistic relationshipsupports2025Source 1DOIPubMed

Cycle number and pressure affected early bubble expansion and acoustic output, whereas long-term bubble behavior and release kinetics were governed by droplet thermophysical properties.

Quoted textsource-backed
While the cycle number and pressure affected early bubble expansion and acoustic output, long-term bubble behavior and release kinetics were governed by the droplet's thermophysical properties.
Claim 4quantitative performancesupports2025Source 1DOIPubMed

Payload release velocities reached 2-4 m/s during ADV and slowed to 0.6-2.7 μm/s after ultrasound.

Quoted textsource-backed
During ADV, payload release velocities reached 2-4 m/s, slowing to 0.6-2.7 μm/s post ultrasound.